Good news if you suffer from rosacea: the FDA approves a new drug to fight it

Rosacea is one of the skin conditions that produces more visits to the dermatologist and also one of the most complicated to combat. It is characterized by producing redness in the skin, dilation of capillaries and even red pimples that can sometimes be confused with acne.

Its causes are still unclear although we do know that the clear and sensitive skin They are much more likely to suffer rosacea. It is curious how with such a common condition the specialists are not very clear about its causes today, and not even the way to combat it, although fortunately little by little we are seeing more progress in this area.

Precisely to all those people who suffer (suffer) from rosacea, a new way has been opened these days to minimize the impact of these types of outbreaks. Until now it can only be fought with specific creams that only help control the outbreak and redness in a timely manner or through treatments such as pulsed light that helps minimize dilated blood vessels, but depending on the stage of the rosacea, it will be necessary quite a few sessions and they are not exactly cheap.

Now, as if the sky fell, the good news comes from the hand of the pharmaceutical company Allergan (Maybe one of you sounds like the owner of the "Botox" brand) that announced a few days ago the approval by the FDA (Food and Drug Administration of the United States) of Rhofade, a new medicine that promises to eliminate redness and rosacea outbreaks in just 12 hours.

What can you expect from Rhofade?

Specifically it is a cream with 1% Oxymetazoline Hydrochloride, mainly created to treat persistent facial erythema, that redness that so much affects those who suffer.

The difference with the treatments on the market to date is that the current medications are directed to the papules and pimples that are created by rosacea, while this new product promises to act directly against erythema, getting a constriction of the capillaries and thus making rosacea much less visible.

This approval means that the drug will reach the American market from May 2017 and its commercialization will probably be available worldwide in a short time, yes, only after medical prescription.